Multi-Omics in Rare Disease Studies: Case Examples
Integrating genomics, transcriptomics, proteomics and metabolomics improves rare disease diagnosis and uncovers mechanisms guiding treatment.
Integrating genomics, transcriptomics, proteomics and metabolomics improves rare disease diagnosis and uncovers mechanisms guiding treatment.
Explains how FDA expanded access gives investigational drugs to rare disease patients, outcomes, barriers and policy solutions.
Clear guide to FDA orphan drug designation: eligibility, 90-day review, tax credits, fee waivers, and 7-year market exclusivity.
Comprehensive roundup of 10 tools that link genetic variants and clinical phenotypes to speed rare disease diagnosis and personalize care.
Comprehensive roundup of 10 tools that link genetic variants and clinical phenotypes to speed rare disease diagnosis and personalize care.
Six modern treatments for rare genetic disorders: small molecules, ASOs, gene therapy, genome editing, combos, and AI-personalized drugs.
How patient-derived iPSCs, organoids, and PDX models improve drug discovery, personalized therapies, and their limits.
Gene editing, ASOs and patient‑derived iPSCs are reshaping rare disease care, enabling faster, tailored treatments and adaptive regulatory pathways.
When a family comes to RareLabs, one of the first things we explain is this: we don't put all our eggs in one basket. Rare disease research is inherently uncertain — no one can predict in advance which approach will yield the most promising results for any given condition.
One of the most powerful tools in modern rare disease research is something that would have sounded like science fiction just twenty years ago: taking a patient's own cells and transforming them into a living, testable model of their disease in the laboratory. This technology — known as induced
A rare disease is any condition that affects fewer than 200,000 people in the United States. But the word "rare" can be deeply misleading. There are over 10,000 known rare diseases worldwide, and collectively they affect an estimated 400 million people globally — roughly 30 million in
Seven-step checklist to choose genetic therapies, use patient-derived models, confirm safety, and plan translation for rare diseases.